Sponsor Directory

AbbVie clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

816

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Atopic Dermatitis
Interventions: Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 33
States / cities: Little Rock, Arkansas • Fountain Valley, California • Fresno, California + 27 more

Conditions: Fibromyalgia
Interventions: Not listed
Lead sponsor: Syneos Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2024
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Pancreatic Cancer
Interventions: ABBV-927, Budiglimab, modified FOLFIRINOX; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Aurora, Colorado • Baltimore, Maryland • Cleveland, Ohio + 1 more

Conditions: Endometriosis
Interventions: Estradiol/Norethindrone Acetate, Placebo for Elagolix, Elagolix, Placebo for E2/NETA; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 681 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 188
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 140 more

Conditions: Psoriasis
Interventions: risankizumab; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 2,170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 79
States / cities: Birmingham, Alabama • Rogers, Arkansas • Bakersfield, California + 65 more

Conditions: Breast Neoplasms, Malignant Neoplasm of Breast
Interventions: Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg, Ibrutinib 420 mg; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Platysma Prominence
Interventions: OnabotulinumtoxinA; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 25
States / cities: Glendale, Arizona • Scottsdale, Arizona • Encino, California + 22 more

Conditions: Functional Constipation, Irritable Bowel Syndrome With Constipation
Interventions: Linaclotide, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 79
States / cities: Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 62 more

Conditions: Platysma Prominence
Interventions: OnabotulinumtoxinA, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 26
States / cities: Glendale, Arizona • Scottsdale, Arizona • Encino, California + 23 more

Conditions: Parkinson's Disease (PD)
Interventions: ABBV-951; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Sun City, Arizona • Loma Linda, California • Orange, California + 9 more

Conditions: Parkinson's Disease (PD)
Interventions: ABBV-951; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 45 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Glendale, California • Orlando, Florida • Grayslake, Illinois + 4 more

Conditions: Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma
Interventions: Venetoclax, Selinexor; Drug
Lead sponsor: Sanjay Mohan; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 4
States / cities: Buffalo, New York • Cleveland, Ohio • Nashville, Tennessee + 1 more

About this AbbVie sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AbbVie is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AbbVie trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AbbVie clinical trials

Filter and sort this sponsor

Live official records

Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

The Savella Pregnancy Registry

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence

A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

About this AbbVie sponsor directory page